Skip to main content

Table 1 Term-course of the patient’s clinical data before and after treatment of omalizumab

From: Serum free IgE guided dose reduction of omalizumab: a case report

Date

Month-20xx

May-13

Jul-13

Sep-13

Nov-13

Jan-16

Jul-16

Sep-16

Jan-17

Before omalizumab

Omalizumab 750 mg/month

Omalizumab 375 mg/month

Blood test

 White blood cell no. (×103)

 

6.4

 

6.2

 

6.8

6.3

7.9

 Neutrophil no. (×103)

 

3.9

 

4

 

5.1

4.5

6.15

 Eosinophil (no.)

 

755

 

241

 

122

227

0.189

 (%)

 

11.8

 

3.9

 

1.8

3.6

2.40%

Lung function test

 FVC (L)

1.93

2.13

2.15

2.28

2.27

2.58

2.26

2.47

 %FVC (%)

78.1

85.9

86.7

92.3

91.9

105.7

92.6

102.5

 FEV1.0 (L)

0.9

0.95

0.88

1.15

1.11

1.36

1.1

1.22

 %FEV1.0 (% predicted)

44.3

46.1

42.7

56.7

54.7

68.5

55.6

63.5

 FEV1.0/FVC (%)

40.9

42

37.1

47.9

48.5

51.1

44.9

48.2

FeNO

 (bbp)

 

40

  

18

21

20

20

Symptom score

 ACT

 

18

 

23

23

25

25

25

  1. Asthma control test (ACT) assesses the frequency of shortness of breath and general asthma symptoms, use of rescue medications, the effect of asthma on daily functioning, and overall self-assessment of asthma control. ACT score 25 points indicates complete control of asthma, under 18 points indicates poor-controlled asthma 10)
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us